MedTrace Logo

Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept

NCT00459706 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 640

Last updated 2013-03-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to explore and compare the perceptions and satisfaction for two different delivery mechanisms for Etanercept (Etanercept Autoinjector and the Etanercept Prefilled Syringe) in patients with rheumatoid arthritis (RA).

Conditions

Interventions

DEVICE

Enbrel 50 mg Prefilled Syringe

Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Prefilled Syringe

DEVICE

Enbrel 50 mg Autoinjector

Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Autoinjector

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Wyeth is now a wholly owned subsidiary of Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2009-04-30
Completion
2009-09-30

Countries

  • Denmark
  • Finland
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00459706 on ClinicalTrials.gov